More than 33,000 devices are affected by this recall. Customers may need to return and replace the purge cassettes included with their devices due to a risk of serious injury or death.
Michiel Voskuil, MD, PhD, presents late-breaking data on the ACC.26 stage.
Patients with coronary artery disease and severe aortic stenosis often undergo PCI before TAVR. According to new data presented at ACC.26, however, deferring PCI is associated with comparable outcomes as well as a reduced bleeding risk.
Adam Greenbaum, MD, presents late-breaking data at ACC.26.
A new embolic protection device from Emboline was noninferior to the FDA-approved Sentinel device in terms of safety and efficacy. In addition, it captured much more TAVR-generated debris and was linked to an improved technical success rate.
The advanced algorithm, which previously received the FDA's breakthrough device designation, detects signs of pulmonary hypertension in standard 12-lead electrocardiograms.
Stavros V. Konstantinides, MD, PhD, presenting late-breaking data at ACC.26 in New Orleans.
New 30-day data presented at ACC.26 helped answer questions cardiologists have had been asking for years. “Thank you for bringing PE into the future," one vascular specialist said from the stage.
